Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1546 to 1560 of 2028 results for nice guidelines

  1. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

  2. Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)

    This guidance has been updated and replaced by NICE guideline NG82.

  3. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

  4. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

  5. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

  6. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

  7. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

  8. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

  9. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

  10. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

  11. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

  12. Impedance-controlled endometrial ablation for menorrhagia (IPG104)

    Summary --> This guidance has been updated and replaced by NICE guideline CG44.

  13. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79

  14. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

  15. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107